Gareth Morgan1,2, MD; Pimpak Prachasilchai3, MD; Worakan Promphan3, MD; Eric Rosenthal1, MD; Kothandam Sivakumar4, MD, DM; Mahesh Kappanayil5, DCH, DNB, FNB; Indriwanto Sakidjan6, MD, PhD; Kevin P. Walsh7, MD; Damien Kenny8, MB, MD; John Thomson9, BM, BS, MD; Nageswara Koneti10, MD, DM; Neeraj Awasthy11, MD, DM; Basil Thanopoulos12, MD, PhD; Supaporn Roymanee13, MD; Shakeel Qureshi1*, MBChB
1. Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2. Childrens’ Hospital of Colorado, Denver, CO, USA; 3. Pediatric Heart Center, Queen Sirikit National Institute of Child Health, Rangsit University, Bangkok, Thailand; 4. Madras Medical Mission Hospital, Chennai, India; 5. Amrita Institute of Medical Sciences and Research Centre, Kochi, India; 6. National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; 7. Mater Hospital, Dublin, Ireland; 8. Our Lady’s Hospital, Crumlin, Dublin, Ireland; 9. Leeds General Infirmary, Leeds, United Kingdom; 10. Care Hospital, Hyderabad, India; 11. Fortis Escorts Heart Institute, New Delhi, India; 12. Agios Loucas Clinic, Thessaloniki, Greece; 13. Prince of Songkla University, Hat Yai, Songkla, Thailand
Aims: The aim of this study was to assess the international procedural and short-term to midterm experience with the new percutaneous Venus P-valve.
Methods and results: Retrospective data of patient characteristics, clinical and imaging follow-up of Venus P-valve implantation outside China were collected. Thirty-eight patients underwent attempted Venus P-valve implantation between October 2013 and April 2017. Thirty-seven valves were successfully implanted during 38 procedures. There was one unsuccessful attempt and there were two valve migrations, one of which required surgical repositioning. The mean follow-up was 25 months with no short-term or midterm valve failure or deterioration in performance. Frame fractures occurred in 27% of patients. The cohort demonstrated a statistically significant reduction in pulmonary regurgitation fraction and indexed right ventricular diastolic volumes at six and 12 months.
Conclusions: Implantation of the Venus P-valve has provided satisfactory short-term to midterm results with high success and low complication rates in an inherently challenging patient substrate.
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Interventions for valvular diseaseOther valvular and structural interventions
Read next article
A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results